Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS- mutant advanced colorectal carcinoma

Abstract Aim Imgatuzumab (GA201) is a novel anti-epidermal growth factor receptor (anti-EGFR) antibody glycoengineered for enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). We investigated the efficacy of imgatuzumab in patients with EGFR-positive, KRAS -mutant advanced colorectal cance...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2014-02, Vol.50 (3), p.496-505
Hauptverfasser:	Delord, Jean-Pierre, Tabernero, Josep, García-Carbonero, Rocío, Cervantes, Andres, Gomez-Roca, Carlos, Bergé, Yann, Capdevila, Jaume, Paz-Ares, Luis, Roda, Desamparados, Delmar, Paul, Oppenheim, David, Brossard, Sophia Soehrman, Farzaneh, Farzin, Manenti, Luigi, Passioukov, Alexandre, Ott, Marion Gabriele, Soria, Jean-Charles
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - therapeutic use Antibody-dependent cell cytotoxicity Biological and medical sciences Cohort Studies Colorectal neoplasms Colorectal Neoplasms - drug therapy Colorectal Neoplasms - enzymology Colorectal Neoplasms - genetics Disease-Free Survival Epidermal growth factor ErbB Receptors - immunology Female GA201 Glycoproteins - therapeutic use Hematology, Oncology and Palliative Medicine Human Humans KRAS protein Male Medical sciences Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Mutation Pharmacology. Drug treatments Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins p21(ras) ras Proteins - genetics Receptor RG7160 Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!